Literature DB >> 33403227

Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape.

Md Shahadat Hossain1, Ithmam Hami1, Md Sad Salabi Sawrav1, Md Fazley Rabbi1, Otun Saha2, Newaz Mohammed Bahadur3, Md Mizanur Rahaman2.   

Abstract

SARS-CoV-2, the novel coronavirus strain responsible for the current pandemic of COVID-19, has rendered the entire humanity suffering. Several months have passed since the pandemic has struck. However, the world is still looking for an effective treatment plan to battle the viral infection. The first vaccine just received emergency approval in December 2020 for use in USA and UK. These are excellent news, however, the worldwide distribution of such vaccine, the possibility of virus mutation and the lack of data regarding the long-term effects of such vaccines are a significant concern. In addition, although remdesivir was recently approved by the FDA to be used as a clinical drug against COVID-19, it hasn't stood out yet as a proven form of therapeutics. Such inability to produce a novel therapy has caused enough inconveniences for the affected people worldwide. Repurposing the already available drugs to fight against the virus seems to be a reasonable option amidst such uncertainty. Given the vast collection of potential treatment candidates to be explored against COVID-19, there is a decent chance that a success in this regard will serve the intermediary purpose of clinically treating the infection until a COVID-19 vaccine is widely distributed worldwide and will be able to treat COVID-19 patients that do not adequately respond to vaccines. Such treatments may prove very useful in future coronavirus outbreaks too. Proper research into these repurposing treatments may yield a certain insight into the field of novel treatment production as well. This review study accumulates a relevant set of information about drugs and vaccines against COVID-19, in terms of their repurposing properties and the specific phases of clinical trials they are undergoing across the world.  A potential timeline is also suggested to estimate when an effective result can be expected from the ongoing clinical trials for a better anticipation of the drug landscape. This study will hopefully help accelerate investment of resources into development and discovery of drugs and vaccines against the infection.
Copyright © 2020, Applied Systems.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; clinical trial; drug repositioning; phases; therapeutics; vaccine

Year:  2020        PMID: 33403227      PMCID: PMC7758544          DOI: 10.15190/d.2020.18

Source DB:  PubMed          Journal:  Discoveries (Craiova)        ISSN: 2359-7232


  94 in total

1.  Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Authors:  Julie Dyall; Christopher M Coleman; Brit J Hart; Thiagarajan Venkataraman; Michael R Holbrook; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Peter B Jahrling; Monique Laidlaw; Lisa M Johansen; Calli M Lear-Rooney; Pamela J Glass; Lisa E Hensley; Matthew B Frieman
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

2.  Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience.

Authors:  Jae-Hoon Ko; Hyeri Seok; Sun Young Cho; Young Eun Ha; Jin Yang Baek; So Hyun Kim; Yae-Jean Kim; Jin Kyeong Park; Chi Ryang Chung; Eun-Suk Kang; Duck Cho; Marcel A Müller; Christian Drosten; Cheol-In Kang; Doo Ryeon Chung; Jae-Hoon Song; Kyong Ran Peck
Journal:  Antivir Ther       Date:  2018-06-20

3.  Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.

Authors:  K S Chan; S T Lai; C M Chu; E Tsui; C Y Tam; M M L Wong; M W Tse; T L Que; J S M Peiris; J Sung; V C W Wong; K Y Yuen
Journal:  Hong Kong Med J       Date:  2003-12       Impact factor: 2.227

4.  Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

Authors:  Pedro M Folegatti; Mustapha Bittaye; Amy Flaxman; Fernando Ramos Lopez; Duncan Bellamy; Alexandra Kupke; Catherine Mair; Rebecca Makinson; Jonathan Sheridan; Cornelius Rohde; Sandro Halwe; Yuji Jeong; Young-Shin Park; Jae-Ouk Kim; Manki Song; Amy Boyd; Nguyen Tran; Daniel Silman; Ian Poulton; Mehreen Datoo; Julia Marshall; Yrene Themistocleous; Alison Lawrie; Rachel Roberts; Eleanor Berrie; Stephan Becker; Teresa Lambe; Adrian Hill; Katie Ewer; Sarah Gilbert
Journal:  Lancet Infect Dis       Date:  2020-04-21       Impact factor: 25.071

5.  A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs.

Authors:  Jianzhong Cao; J Craig Forrest; Xuming Zhang
Journal:  Antiviral Res       Date:  2014-11-28       Impact factor: 5.970

6.  Clinical trials on drug repositioning for COVID-19 treatment.

Authors:  Sandro G Viveiros Rosa; Wilson C Santos
Journal:  Rev Panam Salud Publica       Date:  2020-03-20

7.  Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.

Authors:  Richard D Antrobus; Lynda Coughlan; Tamara K Berthoud; Matthew D Dicks; Adrian Vs Hill; Teresa Lambe; Sarah C Gilbert
Journal:  Mol Ther       Date:  2013-12-30       Impact factor: 11.454

Review 8.  COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!

Authors:  Mohammad S Khuroo; Mohammad Khuroo; Mehnaaz S Khuroo; Ahmad A Sofi; Naira S Khuroo
Journal:  J Clin Exp Hepatol       Date:  2020-06-10

Review 9.  SARS: epidemiology.

Authors:  Moira Chan-Yeung; Rui-Heng Xu
Journal:  Respirology       Date:  2003-11       Impact factor: 6.424

10.  A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.

Authors:  Andrea Cortegiani; Giulia Ingoglia; Mariachiara Ippolito; Antonino Giarratano; Sharon Einav
Journal:  J Crit Care       Date:  2020-03-10       Impact factor: 3.425

View more
  5 in total

1.  Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.

Authors:  Henry R O'Donnell; Tia A Tummino; Conner Bardine; Charles S Craik; Brian K Shoichet
Journal:  J Med Chem       Date:  2021-11-23       Impact factor: 7.446

Review 2.  High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections.

Authors:  Kinal Bhatt; Arjola Agolli; Mehrie H Patel; Radhika Garimella; Madhuri Devi; Efrain Garcia; Harshad Amin; Carlos Domingue; Roberto Guerra Del Castillo; Marcos Sanchez-Gonzalez
Journal:  Discoveries (Craiova)       Date:  2021-03-31

3.  Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus.

Authors:  Nabil A Alhakamy; Osama A A Ahmed; Tarek S Ibrahim; Hibah M Aldawsari; Khalid Eljaaly; Usama A Fahmy; Ahmed L Alaofi; Filippo Caraci; Giuseppe Caruso
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-24

Review 4.  Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children.

Authors:  Alexandra Chera; Antoanela Tanca
Journal:  Discoveries (Craiova)       Date:  2022-06-30

5.  Temporal landscape of mutational frequencies in SARS-CoV-2 genomes of Bangladesh: possible implications from the ongoing outbreak in Bangladesh.

Authors:  Otun Saha; Israt Islam; Rokaiya Nurani Shatadru; Nadira Naznin Rakhi; Md Shahadat Hossain; Md Mizanur Rahaman
Journal:  Virus Genes       Date:  2021-07-12       Impact factor: 2.332

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.